H. Lee Moffitt Cancer Center & Research Institute

Predicine to Introduce PredicineALERT™ MRD Assay and Present Two ctDNA Studies in Genitourinary Cancers at AUA 2023 Annual Meeting

Retrieved on:

Vendredi, avril 28, 2023

DNA, Nucleic acid thermodynamics, TAT, AUA, NMIBC, Liquid biopsy, GU, American Urological Association, Bladder cancer, Index, MRD, UTUC, Patient, Cancer, Annual general meeting, H. Lee Moffitt Cancer Center & Research Institute, CDX, Medical imaging

HAYWARD, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company, announced today that it will present two studies and introduce PredicineALERT™ Minimal Residual Disease (MRD) liquid biopsy assay to genitourinary (GU) cancers at the 2023 American Urological Association (AUA) Annual Meeting held in Chicago between April 28 to May 1, 2023.

Key Points:

HAYWARD, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company, announced today that it will present two studies and introduce PredicineALERT™ Minimal Residual Disease (MRD) liquid biopsy assay to genitourinary (GU) cancers at the 2023 American Urological Association (AUA) Annual Meeting held in Chicago between April 28 to May 1, 2023.
In collaboration with Moffitt Cancer Center, Predicine will present a podium presentation and two posters demonstrating the clinical utility and potential of Predicine’s liquid biopsy platform in bladder cancer and other solid tumors.
Highlights from the studies include PredicineCARE™, urinary tumor DNA detection in treatment-naïve upper tract urothelial carcinoma (UTUC).
“Currently, we are working closely with leading biopharma partners and KOLs on liquid biopsy studies in support of clinical trials, CDx development and commercialization.”

CG Oncology Announces New Phase 2 Data with Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA® (pembrolizumab) in BCG-Unresponsive NMIBC

Retrieved on:

Lundi, mai 1, 2023

Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, AUA, NMIBC, American Urological Association, BCG, MD, Patient, CR, H. Lee Moffitt Cancer Center & Research Institute, Pembrolizumab, Pharmaceutical industry

“The latest results from the CORE-001 trial continue to demonstrate strong efficacy and a favorable safety profile for cretostimogene grenadenorepvec in BCG-Unresponsive NMIBC, a difficult-to-treat patient population,” said Arthur Kuan, Chief Executive Officer, CG Oncology.

Key Points:

“The latest results from the CORE-001 trial continue to demonstrate strong efficacy and a favorable safety profile for cretostimogene grenadenorepvec in BCG-Unresponsive NMIBC, a difficult-to-treat patient population,” said Arthur Kuan, Chief Executive Officer, CG Oncology.
Based on a preliminary data cutoff on March 3, 2023, 34 patients were evaluable for efficacy with a minimum of 3-month follow up.
The combination of cretostimogene grenadenorepvec and pembrolizumab has been generally well tolerated with the adverse event profile consistent with that observed in prior studies of each agent alone.
“We plan to follow the patients in complete remission beyond this time point to ascertain longer-term response to cretostimogene grenadenorepvec and pembrolizumab.”

Envision Healthcare’s 2022 Clinical Impact Report Illustrates the Many Ways Teams Cared for and Positively Impacted Millions of People

Retrieved on:

Jeudi, avril 27, 2023

In 2022, Envision clinicians continued outperforming national quality benchmarks while treating complex medical conditions and authoring two Centers for Medicare & Medicaid Services-approved national clinical quality measures.

Key Points:

In 2022, Envision clinicians continued outperforming national quality benchmarks while treating complex medical conditions and authoring two Centers for Medicare & Medicaid Services-approved national clinical quality measures.
Through programs like Emergency Triage, Treat and Transport (ET3), Envision teams provided patients the right care at the right time and in the right place.
In 2022, Envision redefined its organizational structure to build a transformative care experience for patients and drive clinical innovation.
As part of their passion for improving healthcare worldwide, Envision clinicians and clinical support teammates cared for communities in need through Envision’s Global Health Initiative.

Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on:

Mercredi, avril 26, 2023

CT, Research and development, B-cell lymphoma, CD19, American Society of Clinical Oncology, Cancer, ASCO, CAR, Development, Kite Pharma, ALPHA, SAN, H. Lee Moffitt Cancer Center & Research Institute, Therapy, Society, Safety, Pharmaceutical industry

The ALPHA/ALPHA2 trials were designed to assess the safety, tolerability, and preliminary efficacy at increasing dose levels of ALLO-501 and ALLO-501A, allogeneic CAR T cell product candidates that target CD19.

Key Points:

The ALPHA/ALPHA2 trials were designed to assess the safety, tolerability, and preliminary efficacy at increasing dose levels of ALLO-501 and ALLO-501A, allogeneic CAR T cell product candidates that target CD19.
In addition to exploring cell doses, these studies evaluated escalating doses of ALLO-647, Allogene’s proprietary lymphodepleting antibody designed to prevent premature rejection of AlloCAR T cells.
Allogene is currently enrolling the potentially pivotal Phase 2 ALPHA2 trial of ALLO-501A in large B cell lymphoma (LBCL).
“We are looking forward to sharing updated data from our Phase 1 ALPHA/ALPHA2 trials,” said Zachary Roberts, M.D., Ph.D., Executive Vice President, Research & Development and Chief Medical Officer.

LinKinVax Introduces its Scientific Advisory Board with the Appointment of Three Leading Experts in Immunology and Epidemiology

Retrieved on:

Mercredi, avril 26, 2023

LinKinVax, a clinical-stage biotechnology company, announces the creation of its Scientific Advisory Board with the appointment of three experts in immunology and epidemiology.

Key Points:

LinKinVax, a clinical-stage biotechnology company, announces the creation of its Scientific Advisory Board with the appointment of three experts in immunology and epidemiology.
“We are delighted to welcome Prof. Anna Giuliano, Prof. Sharon Lewin and Prof. Giuseppe Pantaleo to our Scientific Advisory Board.
“We are very pleased to have convinced these leading experts to join our scientific committee.
Their skills and experience in immunology and epidemiology will help guide and optimise all aspects of our clinical development plans for our DC-targeting vaccine platform.

Dyve Biosciences Presents Preclinical Data from Lead Oncology Drug Candidate, DYV800, at the American Association for Cancer Research 2023 Annual Meeting

Retrieved on:

Lundi, avril 24, 2023

Oncology, Health, Clinical Trials, Research, Science, Biotechnology, Poster, Neoplasm, Partnership, Moffitt, GI, Patient, H. Lee Moffitt Cancer Center & Research Institute, TME, Medical imaging

The poster, presented in collaboration with Moffitt, showcased data demonstrating the delivery of intuitive, targeted pH modulation to treat solid tumors.

Key Points:

The poster, presented in collaboration with Moffitt, showcased data demonstrating the delivery of intuitive, targeted pH modulation to treat solid tumors.
Tumor acidosis plays a major role in tumor aggressiveness, invasion, and resistance and is an important target for novel anticancer strategies.
“Dyve continues to advance research in areas where our pH modulation program can unlock decades of ‘settled science’ using our proprietary delivery technology.
, CEO, Dyve Biosciences
The research was published in AACR Journals and is available here: https://aacrjournals.org/cancerres/article/83/7_Supplement/2391/721916

Memora Health Announces $30M Investment To Scale Intelligent Care Enablement Platform With New Health System Partners

Retrieved on:

Mardi, avril 18, 2023

EMR, Health care, Cancer, DRS, Emerge Commerce, North, Virtua Health, Investment, Patient, SAN, AMA, Bain & Company, H. Lee Moffitt Cancer Center & Research Institute, Northwell Health, Nursing

SAN FRANCISCO, April 18, 2023 /PRNewswire/ -- Memora Health, the leading intelligent care enablement platform, today announced a strategic investment of $30 million led by General Catalyst with participation from Northwell Holdings, the venture investment arm of Northwell Health, NorthShore – Edward-Elmhurst Health, PagsGroup, and other strategic investors. The funding also included follow-on investments from existing investors Andreessen Horowitz, Transformation Capital, and Frist Cressey Ventures.

Key Points:

"Memora Health is fundamentally transforming care delivery in our view," said Chris Bischoff, managing director of General Catalyst.
"Their intelligent care enablement platform has found what we see as a unique balance of empowering care teams to give every patient a high-touch care experience while also keeping patients with complex care journeys engaged and proactive in their care.
Memora Health is building the necessary infrastructure to unlock how healthcare organizations scale and deliver next-generation care.
With partners spanning the healthcare industry — including leading health systems, health plans, life science companies, and digital health companies — Memora continues to grow rapidly.

Dyve Announces Poster Presentation at 2023 AACR Annual Meeting

Retrieved on:

Lundi, avril 17, 2023

Dyve Biosciences , Inc. (“Dyve”), a clinical-stage platform biotechnology company with assets in immunology and oncology, today announced that preliminary data from the ongoing pre-clinical partnership with the H. Lee Moffitt Cancer Center & Research Institute will be presented at a poster presentation at the upcoming American Association for Cancer Research (AACR) annual meeting, taking place April 14-19, 2023, in Orlando, Florida.

Key Points:

Dyve Biosciences , Inc. (“Dyve”), a clinical-stage platform biotechnology company with assets in immunology and oncology, today announced that preliminary data from the ongoing pre-clinical partnership with the H. Lee Moffitt Cancer Center & Research Institute will be presented at a poster presentation at the upcoming American Association for Cancer Research (AACR) annual meeting, taking place April 14-19, 2023, in Orlando, Florida.
Dyve will present pre-clinical data from its lead oncology drug candidate, DYV800, a pH modulating agent that targets tumor microenvironment (TME) acidity in solid tumors.
“Dyve continues to advance research in areas where we believe our pH modulation program can achieve the biggest impact for patients and we look forward to sharing new pre-clinical data on our DYV800 program at this year’s AACR.
, Chief Executive Officer, Dyve.

Hillstream BioPharma Selects OncoBay Clinical to Advance Clinical and Regulatory Development for its Lead Drug Candidate HSB-1216, an Anti-Cancer Mechanism

Retrieved on:

Jeudi, avril 13, 2023

Data management, IMCD, Biotechnology, Ferroptosis, H. Lee Moffitt Cancer Center & Research Institute, Research, Pharmaceutical industry, Hillstream loach

HSB-1216, Hillstream’s most advanced candidate, utilizes ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death (IMCD) of drug-resistant cancers.

Key Points:

HSB-1216, Hillstream’s most advanced candidate, utilizes ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death (IMCD) of drug-resistant cancers.
As part of the agreement, OncoBay Clinical’s engagement will provide comprehensive clinical expertise across data management, statistical programming, scientific writing, regulatory affairs and clinical operations services for clinical, and observational studies.
Additionally, OncoBay will leverage the support of a multitude of top scientific advisors and highly experienced teams to support Hillstream.
“OncoBay is a natural partner for us, complementing the oncological expertise of our team,” said Randy Milby, CEO of Hillstream BioPharma.

Tampa General Hospital's John Couris Named a Top Health Care Leader in the U.S. by Becker's Hospital Review

Retrieved on:

Mardi, avril 11, 2023

TAMPA, Fla., April 11, 2023 /PRNewswire/ -- John Couris, president and CEO of Tampa General Hospital (TGH), has been named a top health care leader in the U.S., according to the Becker's Hospital Review 2023 "Great Leaders in Healthcare" list.

Key Points:

TAMPA, Fla., April 11, 2023 /PRNewswire/ -- John Couris, president and CEO of Tampa General Hospital (TGH), has been named a top health care leader in the U.S., according to the Becker's Hospital Review 2023 "Great Leaders in Healthcare" list.
During his tenure, Couris has spearheaded a wide range of programs and partnerships at Tampa General to enhance patient care and inspire broader health care industry innovations.
To accelerate Tampa General forward in creating a health care network to serve the Tampa Bay region and the state of Florida, Couris announced a $550 million master facility plan.
Becker's Hospital Review is a leading source of hospital business news and analysis for the health care industry.